| Title |
Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia.
|
|---|---|
| Published in |
Cochrane database of systematic reviews, July 2009
|
| DOI | 10.1002/14651858.cd006324.pub2 |
| Pubmed ID | |
| Authors |
Cipriani A, Boso M, Barbui C, Barber, Sarah, Olotu, Uwaila, Corsi, Martina, Cipriani, Andrea |
| Abstract |
Although clozapine has been shown to be the treatment of choice in people with schizophrenia that are resistant to treatment, one third to two thirds of people still have persistent positive symptoms despite clozapine monotherapy of adequate dosage and duration. The need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine is the most common reason for simultaneously prescribing a second antipsychotic drug in combination with clozapine. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 25% |
| United Kingdom | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 132 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | <1% |
| Spain | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 129 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 25 | 19% |
| Student > Ph. D. Student | 19 | 14% |
| Student > Postgraduate | 17 | 13% |
| Other | 14 | 11% |
| Student > Bachelor | 12 | 9% |
| Other | 35 | 27% |
| Unknown | 10 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 82 | 62% |
| Psychology | 11 | 8% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Neuroscience | 5 | 4% |
| Nursing and Health Professions | 4 | 3% |
| Other | 12 | 9% |
| Unknown | 13 | 10% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2016.
All research outputs
#2,590,976
of 22,709,015 outputs
Outputs from Cochrane database of systematic reviews
#5,236
of 12,312 outputs
Outputs of similar age
#9,878
of 109,746 outputs
Outputs of similar age from Cochrane database of systematic reviews
#13
of 67 outputs
Altmetric has tracked 22,709,015 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,312 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.3. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 109,746 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.